ipratropium bromide / Generic mfg. - LARVOL DELTA

Structural basis of sodium ion-dependent carnitine transport by OCTN2. (PubMed, Nat Commun) - "Here we report cryo-EM structures of human OCTN2 in three conformations: inward-facing ligand-free, occluded carnitine- and Na+-bound, and inward-facing ipratropium-bound. These structures define key interactions responsible for carnitine transport and identify an allosterically coupled Na+ binding site housed within an aqueous cavity, separate from the carnitine-binding site. Combined with electrophysiology data, we provide a framework for understanding variants associated with SPCD and insight into how OCTN2 functions as the primary human carnitine transporter."

Journal • Metabolic Disorders

Exacerbation of Asthma Among Pediatric Patients Presenting to the Emergency Department. (PubMed, J Clin Med) - "In moderate to severe cases, ipratropium bromide is added. For refractory or life-threatening presentations, intravenous magnesium sulfate, epinephrine, or ventilatory support may be required...Post-discharge care includes thorough caregiver education, medication access, and a personalized asthma action plan to reduce recurrence risk. The effective diagnosis, appropriate exacerbation treatment, monitoring of patients in the post-attack period, as well as successful preventive medication play a key role in the management of pediatric patients with asthma."

Journal • Review • Asthma • Immunology • Pediatrics • Pulmonary Disease • Respiratory Diseases

Depression in children with asthma: Testing a cholinergically mediated "endotype". (PubMed, J Allergy Clin Immunol Glob) - "Higher depressive symptom scores are associated with increased airway responsiveness to inhaled ipratropium in children with asthma and active airway obstruction. These findings suggest the potential for definition of an endotype of asthma with comorbid depression that may benefit from anticholinergic asthma therapies."

Journal • Asthma • CNS Disorders • Depression • Immunology • Inflammation • Mood Disorders • Pediatrics • Psychiatry • Pulmonary Disease • Respiratory Diseases

Medical Management of Rhinitis: Medication Options. (PubMed, Immunol Allergy Clin North Am) - "Intranasal ipratropium, cromolyn, and decongestants offer symptom-specific relief. Oral medications such as antihistamines, leukotriene receptor antagonists, decongestants, and corticosteroids, vary in efficacy and side effects. Emerging therapies like biologics and CRTH2/DPP-4 inhibitors show promise in clinical and preclinical studies."

Journal • Review • Inflammation • PTGDR2

Use of inhaled/nebulised ipratropium bromide in addition to standard first-line treatment with inhaled/nebulised short-acting beta 2-agonist and systemic steroid in the management of acute asthma exacerbations: a systematic review and meta-analysis of randomised controlled trials. (PubMed, Arch Dis Child) - "This review found high-certainty evidence that the IB nebuliser leads to a lower hospitalisation rate. However, when inhaled/nebulised IBs were analysed together, the hospitalisation rate was similar, with moderate certainty evidence. IB improved asthma clinical scores, with low certainty evidence. No difference was reported in other prespecified outcomes.Considering the current evidence and safety profile, inhaled/nebulised IB needs to be considered as an additional treatment for acute asthma exacerbation."

Journal • Retrospective data • Asthma • Critical care • Immunology • Pediatrics • Pulmonary Disease • Respiratory Diseases

Effects of inhaled bronchodilators on dynamic lung mechanics during exercise in COPD: protocol for a randomised, placebo-controlled crossover trial. (PubMed, ERJ Open Res) - "A double-blind, placebo-controlled study involving 25 symptomatic patients (modified Medical Research Council score ≥2) showing functional residual capacity >120% pred and/or >upper limit of normal will receive nebulised salbutamol sulphate (2.5 mg) plus ipratropium bromide (0.5 mg) or normal saline...Confirmation of the study's hypotheses will shed new light on the mechanisms of dyspnoea improvement after inhaled bronchodilators in patients with COPD. Moreover, it will provide a novel integrative platform for assessing the effects of therapeutic approaches targeting their small airways."

Journal • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

A Peculiar Case Of Unilateral Rhinorrhea (ACAAI 2025) - "She has tried Ipratropium, Azelastine, and Fluticasone nose sprays plus oral antihistamines without relief. The patient was referred to Neurosurgery for additional evaluation and treatment of the CSF leak. Discussion Though rare, CSF leaks can occur in the setting of presumed allergic rhinitis with a pan-positive serum allergy panel; consider it in a patient with unilateral refractory rhinorrhea that is largely positional."

Clinical • Allergic Rhinitis • Immunology • Inflammation

Vasomotor Rhinitis: Current Concepts and Emerging Therapies. (PubMed, Cureus) - "Variable therapies include corticosteroids, intranasal antihistamines, and anticholinergics, although ipratropium bromide has had the best dependability results in terms of rhinorrhea...VMR is a condition that has not been adequately studied but is common and requires a progressive management style that relies on triggers. Whereas conventional intranasal treatment is the most appropriate in the first case, nerve-specific treatment has promising outcomes in the case of relapse."

Journal • Review • Allergic Rhinitis • Immunology • Inflammation

Predictive Value of Ipratropium Responsiveness on Posterior Nasal Nerve Neurectomy Outcomes in Chronic Rhinitis (AAO-HNSF 2025) - "Ipratropium response may not be predictive of outcomes for PNN surgical neurectomy. Both ipratropium responders and non-responders may be benefit from PNN surgical neurectomy."

Allergic Rhinitis • Immunology • Inflammation

Comparison of nebulized long-acting muscarinic antagonist (LAMA) revefenacin to short acting muscarinic antagonist (SAMA) ipratropium in COPD patients with acute respiratory failure requiring mechanical ventilation (ERS 2025) - "Nebulized revefenacin once daily in mechanically ventilated COPD patients in ARF is a feasible alternative to SAMA and reduces resource utilization for bronchodilator delivery. Ventilatory mechanics show potentially greater benefit of revefenacin than ipratropium on airway resistance."

Clinical • Cardiovascular • Chronic Obstructive Pulmonary Disease • Immunology • Respiratory Diseases

Assessing the Feasibility of pMDI and Jet Nebulization for Bronchodilator Delivery in AECOPD Patients on NIV: A Randomized Pilot Trial (ERS 2025) - "This pilot trial demonstrates that conducting a randomized comparison of pMDI and jet nebulization for bronchodilator delivery in AECOPD patients on NIV is feasible. Higher serum ipratropium levels with pMDI suggest potential clinical advantages, warranting further investigation in a larger, definitive trial. References Dolovich MB, et al."

Clinical • Chronic Obstructive Pulmonary Disease • Immunology • Respiratory Diseases

Amitriptyline inhibits bronchoconstriction independent of direct receptor binding and reduces number of caveolae. (PubMed, Sci Rep) - "Neither the muscarinic antagonist ipratropium nor the phospholipase C inhibitor U73122, nor the protein kinase C inhibitor chelerythrine diminished the effect of amitriptyline...Furthermore, neither simvastatin (a lipid lowering agent) nor cytochalasin D (an inhibitor of actin polymerization), influenced the inhibitory effect of amitriptyline on bronchoconstriction...A more general mechanism seems likely, as inhibition of single signal transduction pathways failed. Further studies are required to elucidate the underlying mechanisms."

Journal • Asthma • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases

Stepwise Management of Status Asthmaticus Refractory to Initial Therapy: A Case Report. (PubMed, Cureus) - "First, the patient was treated with inhaled beta-2 agonist (albuterol) and corticosteroids (prednisone, dexamethasone, and methylprednisolone). The patient did not improve with these treatments and was given the anticholinergic agent ipratropium bromide in an attempt to increase bronchodilation. Nebulized racemic epinephrine was then added to the patient to optimize maximum bronchodilation and vasoconstriction in an attempt to reduce airway edema and inflammation. To reduce ventilator peak airway pressures through sedation and paralytics, rocuronium and cisatracurium (Nimbex) were administered. Ketamine was added as a sedative and bronchodilator. Propofol and midazolam (Versed) were used to sedate the patient for mechanical ventilation. After the acute episode, maintenance therapy included inhaled corticosteroids (budesonide), a long-acting beta-2 agonist (arformoterol), a long-acting muscarinic antagonist (revefenacin), and montelukast (a leukotriene receptor..."

Journal • Anesthesia • Asthma • Cardiovascular • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases

Effect of Dual Bronchodilation on the Exercise Capacity of Individuals With Non-Cystic Fibrosis Bronchiectasis: Protocol for a Randomized Controlled Double-Blind Crossover Study. (PubMed, JMIR Res Protoc) - P=N/A | "There is no evidence that BDs can improve the exercise capacity of patients with NCFB. This trial will compare the endurance exercise capacity of the same individual with and without dual bronchodilation. If successful, this study will demonstrate that exercise capacity can be improved with the use of BDs in adults with NCFB."

Journal • Bronchiectasis • Genetic Disorders • Immunology • Infectious Disease • Non‐Cystic Fibrosis Bronchiectasis • Novel Coronavirus Disease • Pulmonary Disease • Respiratory Diseases

RARICO: Revefenacin in Acute Respiratory Insufficiency in COPD (clinicaltrials.gov) - P2 | N=21 | Completed | Sponsor: University of California, Los Angeles | Recruiting ➔ Completed | Trial completion date: Jun 2025 ➔ Jan 2025 | Trial primary completion date: Apr 2025 ➔ Jan 2025

Trial completion • Trial completion date • Trial primary completion date • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

Intensive bronchial dilation test: A modified method for evaluating airway reversibility. (PubMed, Asia Pac Allergy) - "After the BDT, they all inhaled the triple atomized drugs (2 mg salbutamol, 1 mg budesonide, and 0.25 mg ipratropium) every 20 minutes in one hour and the lung function test was performed 15 minutes later, which was named as IBDT...The accuracy and sensitivity of the IBDT in evaluating airway reversibility reached 91.46% and 89.71%, respectively, both of which were significantly higher than for the BDT (54.88% and 45.59%, respectively). Our finding suggests that IBDT can more accurately and rapidly evaluate airway reversibility in patients with severe obstructive or mixed ventilation dysfunction when compared to BDT."

Journal • Allergy • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Efficacy and safety of combined nebulization of unfractionated heparin, acetylcysteine, budesonide and ipratropium bromide in hospitalised patients with COVID-19 pneumonia: a randomized controlled clinical trial. (PubMed, BMC Pulm Med) - P=N/A | "The adjunctive HABIT regimen demonstrates favorable efficacy and safety in treating COVID-19 pneumonia."

Clinical • Journal • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

Chronic Nonallergic Rhinosinusitis Associated With Military Burn Pit Exposure. (PubMed, Cureus) - "He was treated with fluticasone and ipratropium intranasal sprays, oral antihistamines, and saline sinus irrigations...He required a course of prednisone and intermittent courses of budesonide sinus irrigations. At the one-year follow-up, he had an excellent treatment response on intranasal sprays and intermittent budesonide sinus irrigations. Enhanced awareness of the impact of toxic exposures on previously deployed individuals' health may help improve their quality of life."

Journal • Allergic Rhinitis • Allergy • Chronic Rhinosinusitis With Nasal Polyps • Immunology • Nasal Polyps • Otorhinolaryngology • Respiratory Diseases • Sinusitis

Effects of aerosol inhalation of budesonide and ipratropium bromide on postoperative respiratory function in children with obstructive sleep apnea syndrome (OSAS) : a single-center randomized controlled study (ChiCTR) - P=N/A | N=485 | Completed | Sponsor: Fujian Children’s Hospital; Fujian Children's Hospital

New trial • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Disorder

A clinical study on the combination of bencycloquidium bromide and montelukast in the treatment of moderate to severe allergic rhinitis. (PubMed, Medicine (Baltimore)) - "The combination of BCQB and MNT had a greater overall effect, compared to MNT monotherapy in improving nasal symptoms such as nasal congestion and rhinorrhea, as well as quality of life in the treatment of (M/S)AR."

Clinical • Journal • Allergic Rhinitis • Conjunctivitis • Immunology • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology • Otorhinolaryngology

Anti-MDA-5 Associated Dermatomyositis With Interstitial Lung Disease: A Case Report (ATS 2025) - "Initial management involved hydroxychloroquine, Moxifloxacin, and nebulization with ipratropium bromide and beclomethasone, but the regimen was adjusted to include high-dose IV Solumedrol, Tofacitinib, and plasmapheresis...Standard treatment for dermatomyositis involves corticosteroids, with steroid-sparing agents (e.g., methotrexate) to manage side effects. A Japanese study demonstrated improved outcomes with "triple therapy" (glucocorticoids, tacrolimus, cyclophosphamide), achieving 89% six-month survival...Conclusions CADM is a rare form of dermatomyositis with minimal or absent muscle symptoms, making early detection challenging. Patients are at high risk for interstitial lung disease, so timely diagnosis is crucial to manage complications and reduce morbidity and mortality."

Case report • Clinical • Alopecia • Cough • Dermatology • Dermatomyositis • Gastrointestinal Disorder • Immunology • Inflammatory Arthritis • Interstitial Lung Disease • Lupus • Musculoskeletal Pain • Myositis • Pulmonary Disease • Respiratory Diseases • Rheumatology • Rosacea • IFIH1

Inhalers or nebulisation of salbutamol in childhood asthma exacerbations in emergency departments. (PubMed, Respir Med) - "The study suggests that salbutamol via pMDI with a holding chamber is as effective as nebulisation for treating mild to moderate childhood asthma exacerbations. This approach results in fewer hospitalisations, reduced side effects, and shorter PED visits. Educating patients on pMDI use and efficacy could further decrease emergency visits for asthma exacerbation."

Journal • Asthma • Immunology • Pediatrics • Pulmonary Disease • Respiratory Diseases

Substrate-specific inhibition of organic cation transporter 1 revealed using a multisubstrate drug cocktail. (PubMed, Drug Metab Dispos) - "Here, we describe a multisubstrate drug cocktail that allows for the simultaneous testing of drug-drug interactions using 8 different victim drugs: fenoterol, salbutamol, sumatriptan, zolmitriptan, ipratropium, trospium, methylnaltrexone, and metformin...Group 1 comprised verapamil, quinidine, fenoterol, and ipratropium, and group 2 comprised metformin, sumatriptan, and trimethoprim...Here, we demonstrate this for organic cation transporter 1 (OCT1, SLC22A1) and presents a drug cocktail designed to identify varying inhibitory potencies in vitro and prevent false-negative drug-drug interaction results during early drug development. This approach can be extended to other polyspecific drug transporters."

Journal • SLC22A1

T-RECS: Treating Respiratory Emergencies in Children Study (clinicaltrials.gov) - P2 | N=44 | Completed | Sponsor: Oregon Health and Science University | Recruiting ➔ Completed | N=150 ➔ 44 | Trial completion date: Sep 2025 ➔ Mar 2025

Enrollment change • Trial completion • Trial completion date • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Direct-to-consumer customized nasal sprays for allergy relief: A market overview (COSM 2025) - "Both share three active ingredients: triamcinolone, ipratropium, and oxymetazoline, but differ in the antihistamine included—Allermi uses azelastine, while Nectar uses olopatadine. Allermi and Nectar are currently the only DTC sellers of customized allergy-relief IN sprays. Both emphasize convenience, transparent pricing, and customized spray formulations, with ongoing provider support. Nectar further positions the customized IN spray as a bridge to SLIT."

Allergy • Immunology